Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity.

Document Type

Article

Publication Date

9-2021

Identifier

DOI: 10.1016/j.survophthal.2021.02.012

Abstract

Over the past decade there has been a paradigm shift in the treatment of retinopathy of prematurity (ROP) with the introduction of antivascular endothelial growth factor (anti-VEGF) treatments. Anti-VEGF agents have the advantages of being easier to administer, requiring less anesthesia, having the potential for improved peripheral vision, and producing less refractive error than laser treatment. On the other hand, it is known that intravitreal administration of anti-VEGF agents lowers VEGF levels in the blood and raises the theoretical concern of intraocular anti-VEGF causing deleterious effects in other organ systems, including the brain. As a result, there has been increased attention recently on neurodevelopmental outcomes in infants treated with anti-VEGF agents. These studies should be put into context with what is known about systemic comorbidities, socioeconomic influences, and the effects of extreme prematurity itself on neurodevelopmental outcomes. We summarize what is known about neurodevelopmental outcomes in extremely preterm infants with ROP, discuss the implications for determining the neurodevelopmental status using neurodevelopmental testing as well as other indicators, and review the existing literature relating to neurodevelopmental outcomes in babies treated for ROP.

Journal Title

Survey of ophthalmology

Volume

66

Issue

5

First Page

877

Last Page

891

Keywords

Neurodevelopment; anti-VEGF; bevacizumab; pediatric retina; retinopathy of prematurity

Link to Full Text
Library Record

Share

COinS